Modified-release hydrocortisone (DuoCort) combines rapid with extended-release hydrocortisone, a modified synthetic derivative of the naturally occurring hormone cortisol. Hydrocortisone binds to the glucocorticoid receptor thus mimicking the natural action of cortisol. Modified-release hydrocortisone is intended for the long-term treatment of AI as a substitute for current glucocorticoid replacement therapy and in clinical trials has been administered orally at 15-40mg once-daily. Most patients also received fludrocortisone at a median dose of 100mg daily.
LY-900014 (ultra-rapid lispro) is in development for the treatment of adult patients with type 1 diabetes mellitus. Type 1 diabetes mellitus is a condition which usually starts early in life and occurs as a result of the pancreas not producing enough (or sometimes any) insulin. This results in elevated blood sugar levels which can damage many organs in the body. Type 1 diabetes usually runs in families. While type 1 diabetes cannot be cured, having regular, at least daily, injections of insulin can keep blood sugar levels stable. However some people, despite having regular injections of insulin, still do not have stable blood sugar levels.